Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp demonstrates a strong positive outlook primarily through its robust growth in the plasma segment, which recorded an impressive 18.6% organic growth, excluding CSL impact, and a notable improvement in adjusted operating margins to 34%. The anticipated increase in FY26 free cash flow to the range of $170-210 million, up from $160-200 million, further indicates the company's financial strength and operational efficiency. Additionally, the improvement in gross margin by 380 basis points year-over-year and an operating margin increase of 250 basis points year-over-year reinforce Haemonetics's ability to enhance profitability amid evolving market conditions.

Haemonetics Corp has experienced a notable decline in its plasma segment, with organic sales dropping 10.1% to $125.4 million, reflecting continued challenges following a prior 4.3% decline in F1Q26. The company's updated financial guidance anticipates a total reported revenue decline of 1% to 4% for FY2026, indicating weaker performance expectations compared to earlier forecasts. Furthermore, the slow organic growth rate of 1.8% in F2Q26, alongside the downward revision of expected hospital growth from 8-11% to 4-7%, suggests increasing pressures on the company’s overall revenue and profitability.